GTMB 7 - Gene Therapy & Molecular Biology

Jekunen et al: Strategy of sensitizing tumor cells with adenovirus-p53 transfectionLowe SW, Bodis S, McClatchey A, Remington L, Ruley HE,Fisher DE, Housman DE, Jacks T. (1994). “p53 status andthe efficacy of cancer therapy in vivo.” Science 266(5186):807-10.Lowe SW, Ruley HE, Jacks T, and Housman DE. (1993). “p53-mediated apoptosis modulates the cytotoxicity of anticanceragents.” Cell 74: 957-967.McPake CR, Shetty S, Kitchingman GR, Harris LC.. (1999).“Wild-Type p53 Induction Mediated by Replication-deficientAdenoviral Vectors.” Cancer Res 59(17): 4247-907.Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, KamidonoS. (1998). “Enhancement of chemosensitivity in humanbladder cancer cells by adenoviral-mediated p53 genetransfer.” Anticancer Res 18(4C): 3087-92.Miyake H, Hara I, Hara S, Arakawa S, Kamidono S. (2000).“Synergistic chemosensitization and inhibition of tumorgrowth and metastasis by adenovirus-mediated P53 genetransfer in human bladder cancer model.” Urology 56(2):332-6.Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA (1996).“Gene therapy for lung cancer: enhancement of tumorsuppression by a combination of sequential systemiccisplatin and adenovirus-mediated p53 transfer.” J ThoracCardiovasc Surg 112: 1372-1376.O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M,Scudiero DA, Monks A, Sausville EA, Weinstein JN, FriendS, Fornace AJ Jr, Kohn KW. (1997). “Characterization of thep53 tumor suppressor pathway in cell lines of the NationalCancer Institute anticancer drug screen and correlations withthe growth-inhibitory potency of 123 anticancer agents.”Cancer Res 57(19): 4285-300.Oren, M. (1992). “p53: the ultimate tumor suppressor gene?”Faseb J 6(13): 3169-76.Osaki S, Nakanishi Y, Takayama K, Pei XH, Ueno H, Hara N.(2000). “Alteration of drug chemosensitivity caused by theadenovirus-mediated transfer of the wild-type p53 gene inhuman lung cancer cells.” Cancer Gene Ther 7(2): 300-7.Parker LP, Wolf JK, Price JE. (2000). “Adenoviral-mediatedgene therapy with Ad5CMVp53 and Ad5CMVp21 incombination with standard therapies in human breast cancercell lines.” Ann Clin Lab Sci 30(4): 395-405.Peller, S. (1998). “Clinical implications of p53: effect onprognosis, tumor progression and chemotherapy response.”Semin. Cancer Biol. 8: 379-387.Perdomo JA, Naomoto Y, Haisa M, Fujiwara T, Hamada M,Yasuoka Y, Tanaka N. (1998). “In vivo influence of p53status on proliferation and chemoradiosensitivity in nonsmall-celllung cancer.” J Cancer Res Clin Oncol 124(1):10-8.Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. (1997).“A model for p53-induced apoptosis.” Nature 389: 300.Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F,Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, OrianaS, Bohm S, Bresciani GL, Spatti G, Zunino F. (1996). “Acomparative study of p53 gene mutations, proteinaccumulation, and response to cisplatin-based chemotherapyin advanced ovarian carcinoma.” Cancer Res 56(4): 689-93.Roth, J. A. (1996). “Modification of tumor-suppressor-geneexpression and induction of apoptosis in non-small-cell lungcancer (NSCLC) with an adenovirus vector expressing wildtypep53 and cisplatin.” Hum Gene Ther 7: 1013-1030.Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH,Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, PistersKM, Putnam JB, Schea R, Shin DM, Walsh GL, DolormenteMM, Han CI, Martin FD, Yen N, Xu K, Stephens LC,McDonnell TJ, Mukhopadhyay T, Cai D. (1996).“Retrovirus-mediated wild-type p53 gene transfer to tumorsof patients with lung cancer.” Nature Medicine 2(9): 985-991.Santoso JT, Tang DC, Lane SB, Hung J, Reed DJ, Muller CY,Carbone DP, Lucci JA 3rd, Miller DS, Mathis JM. (1995).“Adenovirus-based p53 gene therapy in ovarian cancer.”Gynecol Oncol 59(2): 171-8.Schornagel JH, Verweij J, de Mulder PH, Cognetti F, VermorkenJB, Cappelaere P, Armand JP, Wildiers J, de Graeff A,Clavel M, et al, (1995). “Randomized phase III trial ofadatrexate versus methotrexate in patients with metastaticand/or recurrent squamous cell carcinoma of the head andneck: A European Organization for Research and Treatmentof Cancer Head and Neck Cancer Cooperative Group study.”JCO 13: 1649-1655.Schuler M, Herrmann R, De Greve JL, Stewart AK, GatzemeierU, Stewart DJ et al (2001). “Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients ReceivingChemotherapy for Advanced Non-Small-Cell Lung Cancer:Results of a Multicenter Phase II Study.” J Clin Oncol19(6): 1750-1758.Selter, H. and M. Montenarh (1994). “The emerging picture ofp53.” Int J Biochem 26: 154-154.Shahin MS, Hughes JH, Sood AK, Buller RE. (2000). “Theprognostic significance of p53 tumor suppressor genealterations in ovarian carcinoma.” Cancer 89(9): 2006-17.Sherr, C. J. (1994). “G1 phase progression: cycling on cue.” Cell79: 55-62.Stal, O. (1995). “p53 expression and the result of adjuvanttherapy of breast cancer.” Acta Oncologica 34: 767-770.Sugrue MM, Shin DY, Lee SW, Aaronson SA. (1997). “Wildtypep53 triggers a rapid senescence program in humantumor cells lacking functional p53.” Proc Natl Acad Sci U SA 94(18): 9648-53.Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL,Carrasco CH, Connors DG, El-Naggar AK, Fossella F,Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS,Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R,Pisters KM, Putnam JB Jr, Richli WR, Savin M, Waugh MK,et al, (1999). “Adenovirus mediated p53 gene tranfer inadvanced non-small-cell lung cancer.” J Natl Cancer Inst91: 763-771.Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J,Weller M. (1998). “Chemosensitivity of human malignantglioma: modulation by p53 gene transfer.” J Neurooncol39(1): 19-32.Wolf JK, Mills GB, Bazzet L, Bast RC Jr, Roth JA, GershensonDM. (1999). “Adenovirus-mediated p53 growth inhibition ofovarian cancer cells is independent of endogenous p53status.” Gynecol Oncol 75(2): 261-6.von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, MillerDS, Mathis JM. (1998). “In vivo studies of adenovirus-basedp53 gene therapy for ovarian cancer.” Gynecol Oncol 69(3):197-204.Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC.(1996). “Tissue-specific growth suppression andchemosensitivity promotion in human hepatocellularcarcinoma cells by retroviral-mediated transfer of the wildtypep53 gene.” Hepatology 24(5): 1264-8.Yang B, Eshleman JR, Berger NA, Markowitz SD. (1996).“Wild-type p53 protein potentiates cytotoxicity of34